Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
BioMap
AddedFeb 15, 2024
UpdatedJun 18, 2026
BioMap

BioMap

Series A

BioMap, a life science AI firm, pioneers in protein-centric modeling with xTrimo, enhancing drug development.

HQ
Palo Alto, CA, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Founded in 2020 by Robin Li and Wei Liu, BioMap is a pioneering life science AI company focused on protein-centric modeling. Their core mission is to revolutionize drug development through advanced biocomputing technologies. BioMap's flagship product, xTrimo, is the first and largest protein-centric large language model platform, enabling scientists to model biological systems more accurately and derive novel insights from limited data. The company serves the biopharmaceutical industry, aiming to solve critical protein-related drug development challenges.

BioMap boasts a team of over 300 international experts and has garnered attention for its innovative approach to life sciences. Notable figures affiliated with BioMap include co-founders Robin Li and Wei Liu. The company has achieved significant milestones, including the development of xTrimo, which has set new standards in the field of protein modeling. BioMap's impact is evident in its contributions to more efficient and accurate drug discovery processes, positioning it as a leader in the intersection of AI and biotechnology.

BioMap - Similar Companies

Atommap logo

Atommap

BioAI Health logo

BioAI Health

bioaihealth.com

Bionl logo

Bionl

bionl.ai

Biosim logo

Biosim

Manifold Bio logo

Manifold Bio

manifold.bio

Omix.ai logo

Omix.ai

Bioz logo

Bioz

bioz.com

Transition Bio logo

Transition Bio

transitionbio.com

Insitro logo

Insitro

insitro.com

Regenerative Bio logo

Regenerative Bio

regen-bio.us

Bpgbio logo

Bpgbio

bpgbio.com

Profluent Bio logo

Profluent Bio

profluent.bio

AI Proteins logo

AI Proteins

aiproteinstx.com

PipeBio logo

PipeBio

Diffuse Bio logo

Diffuse Bio

diffuse.bio

BioMap - Quick Facts

Who are BioMap's competitors?

Companies similar to BioMap include Atommap, BioAI Health, Bionl and Biosim.

When was BioMap founded?

BioMap was founded in 2020.

Where is BioMap's headquarters located?

BioMap's headquarters is located in Palo Alto, CA, US.

When was BioMap's last funding round?

BioMap's most recent funding round was for $100M (USD) in August 2021.

How much has BioMap raised to-date?

As of Aug 2, 2021, BioMap has raised a total of $100M (USD).

How many employees does BioMap have?

BioMap has 375 employees as of Feb 4, 2024.

BioMap - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • AI Models
  • Drug Discovery
Tags
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software